TTFields in Mesothelioma (The STELLAR Trial): More Stars Needed in the Constellation
By Paul Baas, MD, PhD, and Cornedine J. de Gooijer, MD Posted: June 24, 2020 Recently, a manuscript by Ceresoli et al. was published in The Lancet Oncology.1 The study […] Read more
Lung Cancer in the Brazilian Health System: Screening, Drug Approvals, Barriers to Care, and Success Stories
By Ricardo Sales dos Santos, MD, PhD, and Juliana Franceschini, PhD Posted: June 24, 2020 Dr. Juliana Franceschini Dr. Ricardo Sales dos Santos […] Read more
By Kara Nyberg, PhD Posted: June 24, 2020 Given the variable response to immune checkpoint blockade, researchers have long sought to identify predictive biomarkers beyond PD-L1 to better select patients […] Read more
cfDNA Analysis Suggests EML4-ALK Variant Does Not Influence Response to Lorlatinib
By Kara Nyberg, PhD Posted: June 24, 2020 An exploratory analysis of circulating free DNA (cfDNA) shows that lorlatinib confers potent antitumor activity in pretreated patients with ALK-positive NSCLC regardless […] Read more
Paul G. Kluetz, MD
Posted: June 24, 2020 Paul G. Kluetz, MD, has been named the FDA’s new Deputy Director of the OCE. During his 10 years with the FDA, Dr. Kluetz founded the […] Read more
By Kara Nyberg, PhD Posted: June 24, 2020 The phase II PASSION trial sought to explore the potential synergy between immunotherapy and antiangiogenic drug therapy previously observed in preclinical studies. […] Read more
Multidisciplinary Tumor Boards: Approaches Across Different Institutions
Posted: June 24, 2020 In an effort to provide its audience with information about best practices for multidisciplinary communication, ILCN will be highlighting the approaches of different international institutions. From […] Read more
Shirish Gadgeel, MD
Posted: June 24, 2020 Shirish Gadgeel, MD, is now the Chief of Division of Hematology and Oncology and Associate Director of Patient Experience and Clinical Care at Henry Ford Cancer […] Read more
Prior Pneumonitis as a Risk Factor for Treatment-Associated Pneumonitis With Immune Checkpoint Inhibitor Therapy
By Kara Nyberg, PhD Posted: June 24, 2020 Pneumonitis is a well-known complication associated with immune checkpoint inhibitors (ICI). A collaborative effort between the U.S. Food and Drug Administration (FDA) […] Read more
Karen L. Reckamp, MD, MS
Posted: June 24, 2020 In addition to her roles of Associate Director for Clinical Research at Cedars-Sinai Cancer and Medical Oncology Director of Women’s Guild Lung Institute in the Department […] Read more